TB-008 / Therabene - LARVOL DELTA

PK/PD and preclinical ADME characterization of TB-008, a first-in-class CDK9 degrader in xenograft models (AACR 2026) - "Also, we will report the efficacy of TB-008 in additional xenograft models. Additional preclinical ADME data and PK in higher nonclinical species will be reported."

PK/PD data • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CDK9 • MYC